Lipocine Inc. — Q2 2020 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2020. Lipocine is a clinical-stage biopharmaceutical company developing oral drug-delivery products. It reported no product-sales revenue; its programs remain dependent on regulatory approval, development funding, and potential licensing.
Financial performance and position
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Revenue from product sales | None | None | None | None |
| Research and development expense | $2.27 million | $1.96 million | $4.78 million | $3.91 million |
| General and administrative expense | $1.95 million | $1.39 million | $4.04 million | $2.56 million |
| Net loss | $6.37 million | $3.43 million | $12.14 million | $6.66 million |
| Loss per share, basic and diluted | $0.13 | $0.14 | $0.27 | $0.28 |
| Cash used in operations | Not separately stated | Not separately stated | $7.46 million | $5.56 million |
At June 30, 2020, cash and cash equivalents were $13.84 million, marketable securities were $4.47 million, and restricted cash was $5.00 million. Unrestricted cash, cash equivalents, and marketable securities totaled approximately $18.3 million. Total assets were $23.49 million; total liabilities were $10.40 million, including approximately $6.33 million of debt; and stockholders’ equity was $13.08 million. The $5.00 million restricted cash balance is collateral under the SVB loan agreement and remains restricted until TLANDO receives FDA approval.
Six-month financing cash inflows of $11.68 million—principally from the February equity offering and warrant exercises—exceeded operating and investing cash outflows, increasing cash, cash equivalents, and restricted cash by $4.11 million. No operating margin is meaningful because the filing reports no product revenue.
Changes versus the prior comparable period
- Six-month net loss increased to $12.14 million from $6.66 million. Operating expenses rose to $8.82 million from $6.48 million, driven by higher LPCN 1144 trial spending and legal costs.
- R&D expense increased $0.87 million for the six months; higher LPCN 1144 LiFT study costs were partly offset by lower TLANDO costs after completion of the ABPM study.
- G&A expense increased $1.48 million, primarily reflecting higher legal fees relating to patent litigation and securities litigation.
- A $3.17 million non-cash loss from remeasurement of November 2019 offering warrants contributed to the 2020 loss; no comparable warrant liability loss was reported in 2019. Interest expense declined, while interest and investment income also declined.
- Common shares outstanding increased to 61.38 million from 37.65 million at December 31, 2019, including shares issued in the February offering and warrant exercises. The six-month weighted-average share count was 45.56 million versus 23.99 million.
Outlook, programs, and risks
- TLANDO: After a November 2019 FDA Complete Response Letter citing failure to meet three Cmax secondary endpoints, Lipocine resubmitted its NDA on February 28, 2020 following FDA discussions and reanalysis of existing data. The filing states an August 28, 2020 PDUFA date. Approval and commercial launch remained uncertain; launch would depend on FDA action, supply readiness, COVID-19 conditions, funding, and licensing or building a commercial organization.
- Pipeline: The LiFT Phase 2 study of LPCN 1144 was ongoing. Management expected top-line MRI-PDFF liver-fat data by year-end 2020 and biopsy results by the end of Q2 2021, while warning COVID-19 could delay enrollment, results, or completion. FDA had accepted the LPCN 1148 IND, but management did not expect to start its Phase 2 study in 2020 absent additional capital or a license. No 2020 Phase 3 study was anticipated for TLANDO XR or LPCN 1107 absent additional capital or licensing.
- Liquidity: Management believed available capital would fund projected operating requirements through at least September 30, 2021, based on its current plan. The estimate was subject to uncertainty; the company said it would need additional capital at some point and warned that failure to obtain it could threaten its ability to continue as a going concern. Additional studies, commercial preparation, or litigation could accelerate cash use.
- Debt and financing: SVB deferred principal repayments for six months beginning April 2020; the loan matures June 1, 2022 and carries a $650,000 final payment charge. The company also received a $233,537 PPP loan, some of which may be forgivable if used for eligible expenses. Subsequent to quarter-end, it reported approximately $688,000 from warrant exercises and $4.0 million of gross ATM proceeds from 2.83 million shares.
- Legal and other risks: The derivative shareholder suit was dismissed in its entirety on July 30, 2020. The securities class action remained pending; the company had filed a motion to dismiss and reported a $1.25 million insurance retention. Patent litigation against Clarus concerning JATENZO was ongoing, with trial scheduled to begin February 8, 2021. COVID-19 could disrupt clinical enrollment and data collection, operations, and access to financing. Lipocine also cited reliance on a single TU supplier and limited suppliers for inactive ingredients.
- Unusual accounting item: The warrant liability is a Level 3 fair-value estimate using a Black-Scholes model and can fluctuate materially with share price and other assumptions. The Q2 warrant remeasurement loss was non-cash.
Most important facts for investors to verify
- FDA action on the TLANDO resubmission and the consequences for launch timing, commercialization costs, and release of the $5.0 million restricted cash.
- Whether the LPCN 1144 LiFT trial meets enrollment and data milestones despite COVID-19 disruption.
- Cash burn and financing capacity relative to management’s September 30, 2021 runway estimate, including potential dilution from future equity or warrant exercises.
- Remaining debt obligations, loan covenants, the SVB final payment charge, and the status of PPP loan forgiveness.
- Developments and potential costs in the Clarus patent case and the securities class action, including insurance coverage and retention.